HK1250724A1 - 用於製備經修飾的血管性血友病因子的方法 - Google Patents

用於製備經修飾的血管性血友病因子的方法

Info

Publication number
HK1250724A1
HK1250724A1 HK18109997.4A HK18109997A HK1250724A1 HK 1250724 A1 HK1250724 A1 HK 1250724A1 HK 18109997 A HK18109997 A HK 18109997A HK 1250724 A1 HK1250724 A1 HK 1250724A1
Authority
HK
Hong Kong
Prior art keywords
methods
von willebrand
willebrand factor
preparing modified
modified von
Prior art date
Application number
HK18109997.4A
Other languages
English (en)
Inventor
Stefan Schulte
Hans-Wilhelm Beltz
Sabine Pestel
Thomas Weimer
Matthias Pelzing
Original Assignee
Csl Behring Recombinant Facility Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Recombinant Facility Ag filed Critical Csl Behring Recombinant Facility Ag
Publication of HK1250724A1 publication Critical patent/HK1250724A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK18109997.4A 2015-05-22 2018-08-02 用於製備經修飾的血管性血友病因子的方法 HK1250724A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15168934 2015-05-22
PCT/EP2016/061440 WO2016188905A1 (en) 2015-05-22 2016-05-20 Methods for preparing modified von willebrand factor

Publications (1)

Publication Number Publication Date
HK1250724A1 true HK1250724A1 (zh) 2019-01-11

Family

ID=53191564

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109997.4A HK1250724A1 (zh) 2015-05-22 2018-08-02 用於製備經修飾的血管性血友病因子的方法

Country Status (17)

Country Link
US (3) US10772936B2 (zh)
EP (2) EP3298036B1 (zh)
JP (1) JP6651548B2 (zh)
KR (1) KR20180012303A (zh)
CN (1) CN107810194B (zh)
AU (1) AU2016267539B2 (zh)
BR (1) BR112017024714A2 (zh)
CA (1) CA2986625A1 (zh)
DK (1) DK3298036T3 (zh)
ES (1) ES2912300T3 (zh)
HK (1) HK1250724A1 (zh)
IL (1) IL255711A (zh)
MX (1) MX2017014872A (zh)
RU (1) RU2017145002A (zh)
SG (2) SG10201910900WA (zh)
TW (1) TW201713686A (zh)
WO (1) WO2016188905A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Csl貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子(von Willebrand factor)多肽類
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
US11141466B2 (en) 2017-06-22 2021-10-12 CSL Behring Lengnau AG Modulation of FVIII immunogenicity by truncated VWF
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP4038182A1 (en) * 2019-09-30 2022-08-10 Bioverativ Therapeutics Inc. Lentiviral vector formulations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
EP0910628B1 (en) 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii
AU736993B2 (en) 1997-01-16 2001-08-09 Novo Nordisk A/S Practical in vitro sialylation of recombinant glycoproteins
ATE283034T1 (de) 1998-04-27 2004-12-15 Opperbas Holding Bv Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU2002248329B2 (en) 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
WO2003093313A2 (en) 2002-04-29 2003-11-13 Baxter International Inc. Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
CN101857851A (zh) * 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
CN102139114A (zh) 2003-02-26 2011-08-03 尼克塔治疗公司 聚合物-因子viii部分缀合物
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP3552627A1 (en) 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
PL1824988T3 (pl) 2004-11-12 2018-01-31 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
EP1835938B1 (en) 2004-12-27 2013-08-07 Baxter International Inc. Polymer-von willebrand factor-conjugates
AU2006233638A1 (en) 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation Factor VIII with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
WO2007144173A1 (en) 2006-06-14 2007-12-21 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
CA2657248C (en) 2006-07-13 2018-10-30 Wyeth Production of glycoproteins
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
PT2574677T (pt) 2007-12-27 2017-10-19 Baxalta Inc Processos para cultura de células
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
MX2012005527A (es) 2009-11-13 2012-08-08 Grifols Therapeutics Inc Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
EP2563906B1 (en) 2010-04-26 2017-11-08 Novartis AG Process for cultivation of cho cells
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CA2863328A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
SE537059C2 (sv) * 2012-12-21 2014-12-23 Nätstations Alliansen Ab Elcentral
US20160207977A1 (en) 2013-06-12 2016-07-21 Novo Nordisk A/S Compounds Suitable for Treatment of Haemophilia

Also Published As

Publication number Publication date
DK3298036T3 (da) 2022-06-07
IL255711A (en) 2018-04-30
US11564976B2 (en) 2023-01-31
CN107810194A (zh) 2018-03-16
MX2017014872A (es) 2018-07-06
SG10201910900WA (en) 2020-01-30
US10772936B2 (en) 2020-09-15
BR112017024714A2 (pt) 2018-09-11
JP6651548B2 (ja) 2020-02-19
EP3298036A1 (en) 2018-03-28
CN107810194B (zh) 2021-10-08
JP2018515125A (ja) 2018-06-14
ES2912300T3 (es) 2022-05-25
AU2016267539A1 (en) 2017-11-16
SG11201708754XA (en) 2017-12-28
TW201713686A (en) 2017-04-16
EP3298036B1 (en) 2022-04-06
US10905747B2 (en) 2021-02-02
AU2016267539B2 (en) 2019-12-05
RU2017145002A (ru) 2019-06-24
US20200368327A1 (en) 2020-11-26
CA2986625A1 (en) 2016-12-01
US20210121535A1 (en) 2021-04-29
EP4089109A3 (en) 2023-03-01
US20180153968A1 (en) 2018-06-07
KR20180012303A (ko) 2018-02-05
EP4089109A2 (en) 2022-11-16
WO2016188905A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
HK1253507A1 (zh) 抗 ror1 抗體
HK1254836A1 (zh) 抗-ror1抗體
HK1256116A1 (zh) 抗lag-3抗體
GB201521391D0 (en) Antibodies
GB201521393D0 (en) Antibodies
GB201503534D0 (en) Novel method
HK1232136A1 (zh) 融合蛋白
HK1246804A1 (zh) Tau結合抗體
GB201521382D0 (en) Antibodies
IL247322A0 (en) Antibodies to complement factor bb
GB201512372D0 (en) Novel method
HK1255056A1 (zh) 抗cd115抗體
HK1243429A1 (zh) 抗前-s1 hbv抗體
HK1250724A1 (zh) 用於製備經修飾的血管性血友病因子的方法
GB201508180D0 (en) Antibodies
EP3164150A4 (en) Modified von willebrand factor
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
IL258981A (en) Methods for the production of proteins
GB201509907D0 (en) Antibodies
GB201513033D0 (en) Proteins
HK1244292A1 (zh) 具有改善的半衰期的經修飾的血管性血友病因子
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
AU2014902532A0 (en) Modified von willebrand factor